Remdesivir Enters Clinical Trials as COVID-19 Treatment

April 13, 2020

Remdesivir Enters Clinical Trials as COVID-19 Treatment

Gilead Sciences has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 following the FDA’s rapid review and acceptance of Gilead’s IND filing. Enrollment of the clinical trial began in March — at present, 1000 participants will be entered into the trial. Yourway is committed to advancing trials and has full DTP capacity, which is particularly relevant given the stay-home-orders in place across countries and states.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Pharma Supply Chain & Logistics Innovation Programme EU

May 20-21, 2026
Basel, Switzerland

Schedule a Meeting

Clinical Trial Supply West Coast

September 22-23, 2026
Burlingame, CA

Schedule a Meeting

Media

Articles

Global Reach in Clinical Trials: Beyond Presence to True Execution

Open chat

Hello! How can I help you?